NK Cell Therapies Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 140+ Companies and 160+ Therapies | DelveInsight
DelveInsight’s, “NK Cell Therapies Pipeline Insight, 2025” report provides comprehensive insights about 140+ companies and 160+ pipeline drugs in NK Cell Therapies pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest drugs and treatment options in the NK Cell Therapy Pipeline. Dive into DelveInsight’s comprehensive report today! @ NK Cell Therapy Pipeline Outlook
Key Takeaways from the NK Cell Therapy Pipeline Report
- In June 2025, Artiva Biotherapeutics Inc. announced a Phase 2a study to evaluate the safety and efficacy of AlloNK®, an allogeneic cord blood-derived NK cell therapy, in combination with rituximab in relapsing forms of B-cell dependent rheumatologic diseases.
- DelveInsight’s NK Cell Therapy Pipeline report depicts a robust space with 140+ active players working to develop 160+ pipeline therapies for NK Cell Therapy treatment.
- The leading NK Cell Therapy Companies such as Amgen, Innate Pharma, ImmunityBio, Dragonfly Therapeutics, Glycostem Therapeutics, Athenex, Takeda, Wugen, Affimed Therapeutics, VERAXA, Asclepius Technology Company Group, NKGen Biotech, Sanofi, Indapta Therapeutics, Celularity, GT Biopharma, Biohaven Pharmaceuticals, Acepodia, Allife Medical Science and Technology, Bright Path Biotherapeutics and others.
- Promising NK Cell Therapy Pipeline Therapies such as Tacrolimus, Mycophenolate mofetil, Vax-NK/HCC, Temozolomide, Irinotecan, SLOG Chemotherapy, CellProtect, Isatuximab, and others.
Stay ahead with the most recent pipeline outlook for NK Cell Therapy. Get insights into clinical trials, emerging therapies, and leading companies with NK Cell Therapy @ NK Cell Therapy Treatment Drugs
NK Cell Therapy Emerging Drugs Profile
- Bemarituzumab: Amgen
Bemarituzumab is a first-in-class, isoform-selective, humanized monoclonal antibody in clinical development as a targeted immunotherapy for tumors that overexpress FGFR2b, a splice variant of a receptor for some members of the fibroblast growth factor (FGF) family. Bemarituzumab blocks FGFs 7, 10, and 22 from binding to FGFR2b, and has been engineered for enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) to increase direct tumor cell killing by recruiting natural killer (NK) cells. Clinical results to date suggest that the specificity of bemarituzumab avoids the dose-limiting toxicities that have been noticed with less selective pan-FGFR tyrosine kinase inhibitors that act on multiple FGFRs, including FGFR2. In December 2017, Five Prime and Zai Lab announced a strategic collaboration for the development and commercialization of bemarituzumab in Greater China. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Gastric and Gastroesophageal Junction (GEJ) Cancers.
- Monalizumab: Innate Pharma
Monalizumab (IPH2201) is a potentially first-in-class immune checkpoint inhibitor targeting NKG2A receptors expressed on tumor-infiltrating cytotoxic CD8+ T cells and NK cells. NKG2A is an inhibitory checkpoint receptor for HLA-E, which cancer cells frequently overexpress to protect themselves from NKG2A+ immune cells. By blocking this inhibition, monalizumab prevents HLA-E-expressing tumor cells from evading immune detection. This re-establishes a broad anti-tumor response mediated by NK and T cells, simultaneously enhancing the cytotoxic potential of other therapeutic antibodies. Through its dual action on innate and adaptive immunity, monalizumab holds promise for reactivating immune responses against a variety of solid tumors and hematological malignancies. Currently, the drug is in Phase III for Unresectable Stage III Non-small Cell Lung Cancer and in Phase II for Neoadjuvant NSCLC, other cancer types.
- L1 t-haNK: ImmunityBio
PD-L1.t-haNK cells are a human-derived, allogeneic, natural killer cell line engineered to express a chimeric antigen receptor (CAR) targeting PD-L1, whose origins arise from NantKwest’s proprietary NK-92 (aNK) master cell bank. In addition to targeting PD-L1, PD-L1.t-haNK is engineered to produce intracellular IL-2 for enhanced CD16-targeted antibody-dependent cellular cytotoxicity capabilities. Currently, the drug is in the Phase II clinical studies for the treatment of gastric cancer, pancreatic cancer, squamous cell cancer, glioblastoma, and non-small cell lung cancer.
- M ceNK: ImmunityBio
The first-in-class, memory cytokine-enriched Natural Killer (m-ceNK) cells are the patient’s own NK cells that have been enriched with cytokines, including ImmunityBio’s IL-15 super agonist Anktiva (N-803). These m-ceNK cells, or memory-cytokine enriched NK cells, have been designed for autologous cell therapy, but have also been generated as an allogeneic product from cord blood. M-ceNK provides a unique opportunity in clinics due to its ease of use and potential suitability for use in the ambulatory setting. ImmunityBio has successfully enriched and expanded donor natural killer cells obtained from peripheral blood of donors using a technique called apheresis, to generate a unique NK cell phenotype which exhibits both high cytotoxicity and interferon-g production together with a memory–like effect. M-ceNK cells are currently being investigated in Phase I stage of development for the treatment of Solid Tumor. The company is currently investigating the M-cenk in Phase II stage of development for the treatment of Acute Myeloid Leukemia (AML) and Ovarian cancer, however the details are yet to be announced by the company.
- DF6002: Dragonfly Therapeutics
DF6002 is a monovalent IL-12 immunoglobulin Fc fusion protein proposed to achieve strong anti-tumor efficacy by establishing an inflammatory tumor microenvironment necessary for productive anti-tumor responses. DF6002, Dragonfly’s extended half-life IL12 cytokine, is an investigational immunotherapy being evaluated in adult patients for the treatment of advanced solid tumors. DF6002 has the potential to stimulate effective anti-tumor immunity in patients who are not eligible or not adequately responding to current therapies. The drug is currently being investigated in the Phase I/II stage of development for the treatment of solid tumors.
- oNKord: Glycostem Therapeutics
Allogeneic Natural Killer Cell Therapy (also known as oNKord) comprises natural killer cells (NK-cells) generated ex vivo from umbilical cord blood progenitor cells. The system for the generation of these cells is quite efficient and effective. The process is capable of generating a superior expansion of NK cells, i.e., 5–10,000 fold expansion is achievable. The cells that are produced are of superior quality which is over 95% pure and devoid of contaminating T- and B-cells. These NK cells are already activated and are ready to attack cancer cells. The output of these cells has been proven to be highly reliable and reproducible. As per Glycostem, oNKord are also capable of treating other diseases such as Multiple Myeloma, hematological cancers and solid tumors such as colorectal cancer, head-neck cancer, lung cancer and breast cancer. The drug is currently being evaluated under Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML).
- KUR-501: Athenex
KUR-501 is an autologous cell therapy that is developed by using Cell Medica natural killer T (NKT) cell platform technology in combination with genetically engineered chimeric antigen receptors (CARs) and secretion of the IL-15 cytokine to sustain the activity of the therapeutic cells within the immunosuppressive tumor microenvironment. CAR.GD2-IL-15 NKTs is a GD2 specific chimeric antigen receptor (CAR) and Interleukin-15 Expressing autologous natural killer T-cells. The molecule designed specifically to contain artificial genes called chimeric antigen receptor (CAR), from an antibody called 14g2a that recognizes GD2, a molecule found on almost all neuroblastoma cells (GD2-CAR). The chimeric antigen receptor also contains a gene segment called CD 28 to make the NKT cells last longer. The molecule was further modified by adding a gene expressing Interleukin -15 (IL-15). The combination of these three components showed the most antitumor activity by CAR-expressing NKT cells and improved the cell survival in various animal models. The company currently conducting a Phase I trial in sponsorship with Baylor College of Medicine (BCM) in pediatric patients for the treatment of neuroblastoma.
The NK Cell Therapy Pipeline Report Provides Insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of NK Cell Therapy with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for NK Cell Therapy Treatment.
- NK Cell Therapy Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- NK Cell Therapy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the NK Cell Therapy market
Explore groundbreaking therapies and clinical trials in the NK Cell Therapy Pipeline. Access DelveInsight’s detailed report now! @ New NK Cell Therapy Drugs
NK Cell Therapy Companies
Amgen, Innate Pharma, ImmunityBio, Dragonfly Therapeutics, Glycostem Therapeutics, Athenex, Takeda, Wugen, Affimed Therapeutics, VERAXA, Asclepius Technology Company Group, NKGen Biotech, Sanofi, Indapta Therapeutics, Celularity, GT Biopharma, Biohaven Pharmaceuticals, Acepodia, Allife Medical Science and Technology, Bright Path Biotherapeutics and others.
NK Cell Therapy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
NK Cell Therapy Products have been categorized under various Molecule types such as
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
Unveil the future of Anaplastic Thyroid Cancer Treatment. Learn about new drugs, NK Cell Therapy Pipeline developments, and key companies with DelveInsight’s expert analysis @ NK Cell Therapy Market Drivers and Barriers
Scope of the NK Cell Therapy Pipeline Report
- Coverage- Global
- NK Cell Therapy Companies- Amgen, Innate Pharma, ImmunityBio, Dragonfly Therapeutics, Glycostem Therapeutics, Athenex, Takeda, Wugen, Affimed Therapeutics, VERAXA, Asclepius Technology Company Group, NKGen Biotech, Sanofi, Indapta Therapeutics, Celularity, GT Biopharma, Biohaven Pharmaceuticals, Acepodia, Allife Medical Science and Technology, Bright Path Biotherapeutics and others.
- NK Cell Therapy Pipeline Therapies- Tacrolimus, Mycophenolate mofetil, Vax-NK/HCC, Temozolomide, Irinotecan, SLOG Chemotherapy, CellProtect, Isatuximab, and others.
- NK Cell Therapy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- NK Cell Therapy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on NK Cell Therapy Pipeline Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ NK Cell Therapy Companies, Key Products and Unmet Needs
Table of Contents
- Introduction
- Executive Summary
- Natural Killer (NK) cell therapy: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Late Stage Products (Phase III)
- Bemarituzumab: Amgen
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- L1 t-haNK: ImmunityBio
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- KUR-501: Athenex
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Drug name: Company name
- Inactive Products
- Natural Killer (NK) cell therapy Key Companies
- Natural Killer (NK) cell therapy Key Products
- Natural Killer (NK) cell therapy- Unmet Needs
- Natural Killer (NK) cell therapy- Market Drivers and Barriers
- Natural Killer (NK) cell therapy- Future Perspectives and Conclusion
- Natural Killer (NK) cell therapy Analyst Views
- Natural Killer (NK) cell therapy Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/nk-cell-therapy-pipeline-insight
